Nyloxi-P Tablet contains a combination of Lornoxicam 8 mg and Paracetamol 325 mg, formulated for the effective management of acute and chronic pain conditions. Lornoxicam, a non-steroidal anti-inflammatory drug (NSAID) belonging to the oxicam class, exerts potent analgesic, anti-inflammatory, and antipyretic effects by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. Paracetamol complements this action by providing analgesic and antipyretic effects through central inhibition of prostaglandin synthesis, without significant anti-inflammatory activity. Nyloxi-P is indicated for the relief of moderate to severe pain associated with musculoskeletal disorders, postoperative pain, dental pain, and inflammatory conditions such as osteoarthritis and rheumatoid arthritis. The combination enhances analgesic efficacy while potentially reducing the required dose of each component, minimizing adverse effects. Nyloxi-P should be administered as directed by a healthcare professional, considering contraindications such as hypersensitivity to NSAIDs, active gastrointestinal bleeding, severe hepatic or renal impairment, and cardiovascular risks. Caution is advised in patients with a history of asthma or peptic ulcer disease. Common side effects may include gastrointestinal discomfort, dizziness, and rash. This medication should be used under medical supervision, with attention to dosing guidelines and monitoring for adverse reactions.